Trial Profile
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Apr 2019
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 01 Apr 2019 Safety, efficacy and pharmacokinetic results published in the Cancer Science.
- 17 Jun 2016 Status changed from active, no longer recruiting to completed.
- 14 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.